Hollencrest Capital Management’s Beam Therapeutics BEAM Stock Holding History

Hollencrest Capital Management’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,807	Closed	-$43.1K	–	1245
2026 Q1	$43.1K	Buy	+1,807	New	+$50.1K	﹤0.01%	582
2025 Q1	–	Sell	-26	Closed	-$645	–	1135
2024 Q4	$645	Hold	26	–	–	﹤0.01%	1095
2024 Q3	$637	Hold	26	–	–	﹤0.01%	1033
2024 Q2	$609	Hold	26	–	–	﹤0.01%	1014
2024 Q1	$859	Hold	26	–	–	﹤0.01%	968
2023 Q4	$708	Hold	26	–	–	﹤0.01%	961
2023 Q3	$625	Hold	26	–	–	﹤0.01%	990
2023 Q2	$830	Hold	26	–	–	﹤0.01%	1036
2023 Q1	$796	Hold	26	–	–	﹤0.01%	1036
2022 Q4	$1.02K	Buy	+26	New	+$1.17K	﹤0.01%	1007

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Hollencrest Capital Management's BEAM Position: Q2 2026 in Review

Hollencrest Capital Management sold out of Beam Therapeutics (BEAM) in Q2 2026, closing a stake of 1,807 shares — an estimated $43.1K sold.

Hollencrest Capital Management first reported a position in BEAM in Q4 2022 and held it in 10 quarters. The position peaked at $43.1K in Q1 2026. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

Hollencrest Capital Management reported no remaining Beam Therapeutics position as of Q2 2026 after selling out during the quarter.
Hollencrest Capital Management sold 1,807 Beam Therapeutics shares in Q2 2026, an estimated $43.1K.
Hollencrest Capital Management first reported a position in Beam Therapeutics in Q4 2022 and held it in 10 quarters.
Hollencrest Capital Management's Beam Therapeutics position peaked at $43.1K in Q1 2026.
277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Hollencrest Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.